Health
Immunotherapy after surgery offers recurrence-free survival advantage for patients with high-risk melanoma – News-Medical.Net
Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either…
Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, will be presented at the ASCO annual meeting June 6, 2021.
Researchers also measured overall survival and found no statistically significant difference in overall survival rates between the two groups of patients…
-
Business23 hours agoThe ultimate Australian stocks to buy and hold for 10+ years
-
Noosa News19 hours agoSouthern NSW farmers call for financial relief as ongoing drought takes a toll
-
Noosa News19 hours agoLNP Premier David Crisafulli announces ‘Queensland’s royal commission’ into CFMEU
-
Noosa News18 hours agoMan stabbed in physical altercation on the Sunshine Coast